Acid, Hyaluronic, Intraarticular
FDA adverse event reports and recall history for acid, hyaluronic, intraarticular (product code MOZ), from the public MAUDE corpus and the live FDA recall database.
- Total reports
- 8,410
- Deaths
- 307
- Injuries
- 5,581
- Malfunctions
- 678
Reports per year
Source: FDA adverse event reports by year received, 2012–2026. Reporting paused twice in 2026 during FDA reporting-system changes and has since resumed.
Recent recalls
- 2010-05-21TerminatedProcess control
Euflexxa (1% sodium hyaluronate). Pre-filled syringe, Rx only, 3 syringes per carton; Manufactured by Ferring Pharmaceuticals In, Parsippany, NJ 07054; Manufactured by Bio-Technology General (Israel Ltd. Be er Tuvia, Kiryat Malachi 83104 Israel. Indicated for the treatment of pain in osteoarthritis of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics.
Out of Specification results for molecular weight or viscosity through the established expiration date.
- TerminatedEnvironmental control
Synvisc-One (hylan G-F 20), 6mL delivered from a 10mL syringe Product Usage: A elastoviscous high molecular weight fluid containing hylan A and hylan B polymers produced from chicken combs. Synvisc-One is administered as a single intra-articular injection. Synvisc-One is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics, e.g., acetaminophen.
Contamination with Methylbacterium thiocyanatum
Monitor acid, hyaluronic, intraarticular automatically
DeviceWatch watches FDA adverse events and recalls for the products you care about, summarizes clinical narratives with AI and alerts you when a safety signal emerges.